Antipsychotic Use in Children: FDA Panel Rejects FDA Soft-Peddle Approach
"The committee’s concerns are part of a growing chorus of complaints about the increasing use of antipsychotic medicines in children and teenagers.
Letter of Complaint to FDA Commissioner, 2007
Complaint about a surge of FDA administrative approvals for expanded use of highly toxic antipsychotic drugs for children. Approvals were determined by Dr. Thomas Laughren after secret deliberations–without disclosure of scientific data, without an advisory panel or open public discussion.
Activists Take on Eli Lilly Over Off-Label Marketing & Harm Caused by Zyprexa
The deceptive marketing of antipsychotic drugs has prompted new advocacy group to launch "The Just Say "Know" to Prescription Drugs Campaign." Its goal is to get one million people to stop and reevaluate the medications they are taking.
Lilly Marketing Zyprexa Challenged by Stat AGs–NYT_Antipsychotics: Off-label Use
State Attorney Generals are investigating the off-label marketing of Zyprexa–which, if documented is a federal crime.
AHRQ No Evidence to Support Off-Label Uses of Atypical Antipsychotics
"Most off-label use occurs without scientific support."
Assaultive Prescribing of Psych Drugs for Children
Australian psychiatrist: "Does anyone else see tardive dysmentia after atypicalantipsychotics?"
U.S. Doctors are prescribing the antidepressant, Effexor (150mg) for infants under age one!
Conflict of Interest | Corrupt Practices | Gov. Medical Malfeasance | Government Agencies | Pharma Corrupt Influence
Former State Pharmacist (Pennsylvania) Faces Criminal charges
Steven Fiorello, former Chief Pharmacist for the State of Pennsylvania, was arraigned on on Tuesday, November 21, 2006, on Felony and Misdemeanor charges related to his accepting money from drug companies whose drugs he put on the state Formulary.
Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug
Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug Thu, 29 Sep 2005 Reuters reports that Eli Lilly is adding a Black Box suicide warning to the Strattera label. Strattera has been promoted as a “non stimulant” treatment for ADHD. Since ADHD…
Risks: Drugs / Vaccines / Trials / Treatments
Risks: Drugs / Vaccines / Trials / Treatment Evidence of antidepressant harm Oct 14, 2005: Andrew Finkelstein Letter to Dr. Russell Katz, Director, Neuropharmacological Drug Products, FDA about FDA’s Failure to Warn about Neurontin-Suicides Aug 29: FDA Response to Utah Court Must Be Truthful Re: Zoloft / SSRI Suicidal Risks…
Merck / Johnson & Johnson/ Lilly-Zyprexa: $690 Million settlement / a Flowering of Diabetes Drugs
Merck / Johnson & Johnson/ Lilly-Zyprexa: $690 Million settlement / a Flowering of Diabetes Drugs Fri, 10 Jun 2005 A cluster of news reports about three pillars of the pharmaceutical industry– Merck, Eli Lilly, and Johnson & Johnson–leave no doubt that this industry has shown its disregard for the welfare…
Cash Interests Taint Drug Advice – NATURE / Death a Risk of Antipsychotics – AP
Cash Interests Taint Drug Advice – NATURE / Death a Risk of Antipsychotics – AP Sun, 23 Oct 2005 An investigation by the journal, NATURE (the largest of its kind) reveals that not only do conflicts of interest taint the conduct and outcome of clinical trials, the authors who formulate…
Pfizer Admits Guilt in Promotion of Neurontin–Agrees to Pay $430 Million
Pfizer Admits Guilt in Promotion of Neurontin–Agrees to Pay $430 Million Sun, 16 May 2004 A lawsuit initiated by Dr. David Franklin, a whistleblower, has been settled: Pfizer pleaded guilty to criminal fraud in the promotion of Neurontin, and agreed to pay $430 million. This case is but an example…